Bivalirudin versus heparin use for patients undergoing PPCI

The Lancet

Volumn 385, Issue 9982, 2015, Pages 2045-

  Shah, Rahman ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PEPTIDE FRAGMENT;

BLEEDING; CARDIOVASCULAR DISEASE; DISEASE SEVERITY; HEART INFARCTION; HUMAN; LETTER; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; CORONARY STENOSIS; FEMALE; MALE; PROCEDURES; RADIOGRAPHY; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY STENOSIS; FEMALE; HEPARIN; HUMANS; MALE; PEPTIDE FRAGMENTS;

EID: 84929938522     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60988-6     Document Type: Letter

References (5)

1. A Shahzad, I Kemp, C Mars for the HEAT-PPCI trial investigators Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial Lancet 384 2014 1849 1858
2. GW Stone, B Witzenbichler, G Guagliumi for the HORIZONS-AMI Trial Investigators Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
3. PG Steg, A van't Hof, CW Hamm for the EUROMAX Trial Investigators Bivalirudin started during emergency transport for primary PCI N Engl J Med 369 2013 2207 2217
4. Y Han, J Guo, Y Zheng for the BRIGHT Investigators Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial JAMA 313 2015 1336 1346
5. EW Steyerberg, PM Bossuyt, KL Lee Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? Am Heart J 139 2000 745 751